The regulatory model designed to foster new competitors, more consumer choice and lower prices has enjoyed modest success, at ...

Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial; ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative ...

Neumora is currently conducting preclinical DIO studies to characterize the potential of NMRA-215 in obesity and expects to report data in 2025. Additionally, Neumora expects to progress NMRA-215 into ...

Harry Springer, 21, has been sentenced to more than nine years in prison after making bomb threats against Compass High ...

Clinical pipeline advanced, with key Phase 3 trials in major depressive disorder and new studies entering clinic. These 10 stocks could mint the next wave of millionaires › Neumora Therapeutics ...

GAAP revenue more than doubled to $22.3 million in Q2 2025 compared to Q2 2024, significantly surpassing the Q2 2025 GAAP revenue estimate of $11.68 million. GAAP earnings per share improved to $(1.34 ...

On track for proof-of-concept Phase 1b data no later than this fall in participants with recurrent genital herpes for long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidates, ...

New deal would compensate roughly 6,500 doctors in family health organizations for administrative work that is unpaid under ...

Terns, once a rising star in obesity and the MASH space, will refocus on cancer and partner out a handful of obesity assets.